nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—CHRM4—Monoamine GPCRs—DRD4—conduct disorder	0.0394	0.0394	CbGpPWpGaD
Solifenacin—CHRM5—Monoamine GPCRs—DRD4—conduct disorder	0.0377	0.0377	CbGpPWpGaD
Solifenacin—CHRM4—Amine ligand-binding receptors—DRD4—conduct disorder	0.0331	0.0331	CbGpPWpGaD
Solifenacin—CHRM5—Amine ligand-binding receptors—DRD4—conduct disorder	0.0317	0.0317	CbGpPWpGaD
Solifenacin—CHRM1—Monoamine GPCRs—DRD4—conduct disorder	0.0265	0.0265	CbGpPWpGaD
Solifenacin—CHRM3—Monoamine GPCRs—DRD4—conduct disorder	0.0265	0.0265	CbGpPWpGaD
Solifenacin—CHRM2—Monoamine GPCRs—DRD4—conduct disorder	0.0262	0.0262	CbGpPWpGaD
Solifenacin—CHRM4—Monoamine GPCRs—HTR2A—conduct disorder	0.0257	0.0257	CbGpPWpGaD
Solifenacin—CHRM5—Monoamine GPCRs—HTR2A—conduct disorder	0.0246	0.0246	CbGpPWpGaD
Solifenacin—CHRM1—Amine ligand-binding receptors—DRD4—conduct disorder	0.0223	0.0223	CbGpPWpGaD
Solifenacin—CHRM3—Amine ligand-binding receptors—DRD4—conduct disorder	0.0222	0.0222	CbGpPWpGaD
Solifenacin—CHRM2—Amine ligand-binding receptors—DRD4—conduct disorder	0.022	0.022	CbGpPWpGaD
Solifenacin—CHRM4—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0216	0.0216	CbGpPWpGaD
Solifenacin—CHRM5—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0207	0.0207	CbGpPWpGaD
Solifenacin—CHRM1—Monoamine GPCRs—HTR2A—conduct disorder	0.0173	0.0173	CbGpPWpGaD
Solifenacin—CHRM3—Monoamine GPCRs—HTR2A—conduct disorder	0.0173	0.0173	CbGpPWpGaD
Solifenacin—CHRM2—Monoamine GPCRs—HTR2A—conduct disorder	0.0171	0.0171	CbGpPWpGaD
Solifenacin—CHRM4—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.0169	0.0169	CbGpPWpGaD
Solifenacin—CHRM5—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.0162	0.0162	CbGpPWpGaD
Solifenacin—CHRM1—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0146	0.0146	CbGpPWpGaD
Solifenacin—CHRM3—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0145	0.0145	CbGpPWpGaD
Solifenacin—CHRM2—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0144	0.0144	CbGpPWpGaD
Solifenacin—CYP3A4—Estrogen metabolism—COMT—conduct disorder	0.0135	0.0135	CbGpPWpGaD
Solifenacin—CHRM3—GPCRs, Other—DRD4—conduct disorder	0.0118	0.0118	CbGpPWpGaD
Solifenacin—CHRM2—GPCRs, Other—DRD4—conduct disorder	0.0116	0.0116	CbGpPWpGaD
Solifenacin—CHRM4—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0116	0.0116	CbGpPWpGaD
Solifenacin—CHRM1—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.0114	0.0114	CbGpPWpGaD
Solifenacin—CHRM3—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.0113	0.0113	CbGpPWpGaD
Solifenacin—CHRM2—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.0112	0.0112	CbGpPWpGaD
Solifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0111	0.0111	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—CGA—conduct disorder	0.00885	0.00885	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—CGA—conduct disorder	0.00847	0.00847	CbGpPWpGaD
Solifenacin—CHRM4—G alpha (i) signalling events—DRD4—conduct disorder	0.00818	0.00818	CbGpPWpGaD
Solifenacin—CHRM2—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.00804	0.00804	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00784	0.00784	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00781	0.00781	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00773	0.00773	CbGpPWpGaD
Solifenacin—CHRM3—GPCRs, Other—HTR2A—conduct disorder	0.00767	0.00767	CbGpPWpGaD
Solifenacin—CHRM4—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.0076	0.0076	CbGpPWpGaD
Solifenacin—CHRM2—GPCRs, Other—HTR2A—conduct disorder	0.00759	0.00759	CbGpPWpGaD
Solifenacin—CHRM5—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00727	0.00727	CbGpPWpGaD
Solifenacin—CHRM1—Circadian rythm related genes—SLC6A4—conduct disorder	0.00665	0.00665	CbGpPWpGaD
Solifenacin—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00651	0.00651	CbGpPWpGaD
Solifenacin—CHRM1—Circadian rythm related genes—DRD4—conduct disorder	0.00625	0.00625	CbGpPWpGaD
Solifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00623	0.00623	CbGpPWpGaD
Solifenacin—CHRM5—G alpha (q) signalling events—HTR2A—conduct disorder	0.00614	0.00614	CbGpPWpGaD
Solifenacin—CHRM2—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.00605	0.00605	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—CGA—conduct disorder	0.00597	0.00597	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—CGA—conduct disorder	0.00595	0.00595	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—CGA—conduct disorder	0.00589	0.00589	CbGpPWpGaD
Solifenacin—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00549	0.00549	CbGpPWpGaD
Solifenacin—CHRM2—G alpha (i) signalling events—DRD4—conduct disorder	0.00545	0.00545	CbGpPWpGaD
Solifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00512	0.00512	CbGpPWpGaD
Solifenacin—CHRM3—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00511	0.00511	CbGpPWpGaD
Solifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00506	0.00506	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—CGA—conduct disorder	0.005	0.005	CbGpPWpGaD
Solifenacin—CHRM4—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00496	0.00496	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—DRD4—conduct disorder	0.00496	0.00496	CbGpPWpGaD
Solifenacin—CHRM2—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.00493	0.00493	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—CGA—conduct disorder	0.00479	0.00479	CbGpPWpGaD
Solifenacin—CHRM5—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00475	0.00475	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—DRD4—conduct disorder	0.00475	0.00475	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—CGA—conduct disorder	0.00454	0.00454	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00439	0.00439	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00437	0.00437	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—CGA—conduct disorder	0.00435	0.00435	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00433	0.00433	CbGpPWpGaD
Solifenacin—CHRM1—G alpha (q) signalling events—HTR2A—conduct disorder	0.00432	0.00432	CbGpPWpGaD
Solifenacin—CHRM3—G alpha (q) signalling events—HTR2A—conduct disorder	0.00431	0.00431	CbGpPWpGaD
Solifenacin—CHRM4—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00425	0.00425	CbGpPWpGaD
Solifenacin—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00416	0.00416	CbGpPWpGaD
Solifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00407	0.00407	CbGpPWpGaD
Solifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00387	0.00387	CbGpPWpGaD
Solifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00385	0.00385	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—CGA—conduct disorder	0.00337	0.00337	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—CGA—conduct disorder	0.00336	0.00336	CbGpPWpGaD
Solifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00334	0.00334	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—DRD4—conduct disorder	0.00334	0.00334	CbGpPWpGaD
Solifenacin—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00333	0.00333	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—DRD4—conduct disorder	0.00333	0.00333	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—CGA—conduct disorder	0.00333	0.00333	CbGpPWpGaD
Solifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.0033	0.0033	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—DRD4—conduct disorder	0.0033	0.0033	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—HTR2A—conduct disorder	0.00323	0.00323	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—HTR2A—conduct disorder	0.0031	0.0031	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CGA—conduct disorder	0.00306	0.00306	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CGA—conduct disorder	0.00305	0.00305	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CGA—conduct disorder	0.00302	0.00302	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00286	0.00286	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00285	0.00285	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00283	0.00283	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—DRD4—conduct disorder	0.0028	0.0028	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CGA—conduct disorder	0.00268	0.00268	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—DRD4—conduct disorder	0.00268	0.00268	CbGpPWpGaD
Solifenacin—CHRM2—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00261	0.00261	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CGA—conduct disorder	0.00257	0.00257	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—DRD4—conduct disorder	0.00254	0.00254	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—DRD4—conduct disorder	0.00244	0.00244	CbGpPWpGaD
Solifenacin—CYP3A4—Biological oxidations—COMT—conduct disorder	0.00223	0.00223	CbGpPWpGaD
Solifenacin—CYP3A4—Biological oxidations—MAOA—conduct disorder	0.00221	0.00221	CbGpPWpGaD
Solifenacin—CYP3A4—Metapathway biotransformation—COMT—conduct disorder	0.00219	0.00219	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—HTR2A—conduct disorder	0.00218	0.00218	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—HTR2A—conduct disorder	0.00217	0.00217	CbGpPWpGaD
Solifenacin—CHRM1—Circadian rythm related genes—EP300—conduct disorder	0.00216	0.00216	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—CGA—conduct disorder	0.00216	0.00216	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—HTR2A—conduct disorder	0.00215	0.00215	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—WASF1—conduct disorder	0.00215	0.00215	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—WASF1—conduct disorder	0.00206	0.00206	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—DRD4—conduct disorder	0.00189	0.00189	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—DRD4—conduct disorder	0.00188	0.00188	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—DRD4—conduct disorder	0.00186	0.00186	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—HTR2A—conduct disorder	0.00183	0.00183	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CGA—conduct disorder	0.00181	0.00181	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CGA—conduct disorder	0.0018	0.0018	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CGA—conduct disorder	0.00179	0.00179	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—HTR2A—conduct disorder	0.00175	0.00175	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—DRD4—conduct disorder	0.00171	0.00171	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—DRD4—conduct disorder	0.00171	0.00171	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—DRD4—conduct disorder	0.00169	0.00169	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—HTR2A—conduct disorder	0.00166	0.00166	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—HTR2A—conduct disorder	0.00159	0.00159	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—DRD4—conduct disorder	0.0015	0.0015	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—WASF1—conduct disorder	0.00145	0.00145	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—WASF1—conduct disorder	0.00145	0.00145	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—DRD4—conduct disorder	0.00144	0.00144	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—WASF1—conduct disorder	0.00143	0.00143	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—HTR2A—conduct disorder	0.00123	0.00123	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—HTR2A—conduct disorder	0.00123	0.00123	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—HTR2A—conduct disorder	0.00122	0.00122	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—HTR2A—conduct disorder	0.00112	0.00112	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—HTR2A—conduct disorder	0.00112	0.00112	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—HTR2A—conduct disorder	0.0011	0.0011	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—DRD4—conduct disorder	0.00101	0.00101	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—DRD4—conduct disorder	0.00101	0.00101	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—DRD4—conduct disorder	0.001	0.001	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—HTR2A—conduct disorder	0.00098	0.00098	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—COMT—conduct disorder	0.000973	0.000973	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—MAOA—conduct disorder	0.000967	0.000967	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—HTR2A—conduct disorder	0.000939	0.000939	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CGA—conduct disorder	0.000843	0.000843	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—HTR2A—conduct disorder	0.000661	0.000661	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—HTR2A—conduct disorder	0.000659	0.000659	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—HTR2A—conduct disorder	0.000652	0.000652	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—EP300—conduct disorder	0.000519	0.000519	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—EP300—conduct disorder	0.000497	0.000497	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—EP300—conduct disorder	0.000417	0.000417	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—COMT—conduct disorder	0.000381	0.000381	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—MAOA—conduct disorder	0.000378	0.000378	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—EP300—conduct disorder	0.00035	0.00035	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—EP300—conduct disorder	0.000349	0.000349	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—EP300—conduct disorder	0.000346	0.000346	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—EP300—conduct disorder	0.000163	0.000163	CbGpPWpGaD
